Study guide
11.4 Hemolytic Disease of the Fetus and Newborn (HDFN) and Rh Immune Globulin
Philippine Medical Technologists Licensure Examination MTLE
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Clinical Chemistry: Laboratory Operations, Instrumentation, Reagents, Quality Assurance, and Safety
1.1 Specimen Collection, Preanalytical Variables, and Interferences 1.2 Clinical Chemistry Instrumentation, Photometry, and Automation 1.3 Quality Control, Westgard Rules, Calibration, and Laboratory Mathematics 1.4 Reagent Preparation, Laboratory Water, Glassware, Pipettes, and Centrifuges 1.5 Laboratory Safety: Chemical, Fire, Electrical, Biological, and Physical Hazards
2 Chapter 2: Clinical Chemistry: Carbohydrates, Lipids, Proteins, Non-Protein Nitrogen, and Liver Function
2.1 Glucose Homeostasis, Diagnostic Criteria for Diabetes Mellitus, and Glycemic Monitoring 2.2 Lipids, Lipoproteins, Apolipoproteins, and Coronary Heart Disease Risk Assessment 2.3 Serum Proteins, Albumin, Globulins, and Serum Protein Electrophoresis Patterns 2.4 Non-Protein Nitrogen Compounds: Urea, Creatinine, Uric Acid, and Renal Function 2.5 Liver Function Tests, Bilirubin Metabolism, and Jaundice
3 Chapter 3: Clinical Chemistry: Electrolytes, Blood Gases, Enzymology, Endocrinology, and Toxicology
3.1 Water Balance, Electrolytes, Osmolality, and Anion Gap Calculations 3.2 Blood Gas Analysis, Oxygenation, and Acid-Base Homeostasis 3.3 Clinical Enzymology: Enzyme Kinetics, Cardiac Biomarkers, and Hepatic and Pancreatic Enzymes 3.4 Endocrinology: Hormone Physiology and Endocrine Function Testing 3.5 Therapeutic Drug Monitoring and Clinical Toxicology
4 Chapter 4: Bacteriology: Specimen Management, Media, Staining, and Biosafety
4.1 Specimen Collection, Transport, Processing, and Microscopic Staining 4.2 Culture Media Classification, Quality Control, and Inoculation Techniques 4.3 Sterilization, Disinfection, Decontamination, and Biosafety Containment 4.4 Antimicrobial Susceptibility Testing Methods, Standardization, and Resistance Mechanisms
5 Chapter 5: Diagnostic Bacteriology: Major Pathogenic Bacteria
5.1 Medically Important Gram-Positive Cocci: Staphylococci, Streptococci, and Enterococci 5.2 Medically Important Gram-Negative Bacilli: Enterobacterales and Non-Fermenters 5.3 Fastidious, Microaerophilic, and Anaerobic Bacteria 5.4 Mycobacteria, Spirochetes, Atypical Bacteria, and Public Health Microbiology
6 Chapter 6: Medical Parasitology, Mycology, and Diagnostic Virology
6.1 Stool Examination Techniques and Intestinal Nematodes 6.2 Tissue Nematodes, Filarial Worms, Cestodes, and Trematodes 6.3 Medical Protozoology: Intestinal, Urogenital, and Blood/Tissue Protozoa 6.4 Medical Mycology: Yeasts, Dermatophytes, Dimorphic Fungi, and Opportunistic Molds 6.5 Clinical Virology: Viral Structure, Specimen Handling, and Diagnostic Methods
7 Chapter 7: Hematology: Specimen Collection, Routine Parameters, Instrumentation, and Manual Methods
7.1 Blood Specimen Collection, Anticoagulants, Preanalytical Variables, and Specimen Quality 7.2 Automated Cell Counting Principles, Complete Blood Count Parameters, and Erythrocyte Indices 7.3 Reticulocyte Evaluation, Supravital Staining, and Erythrocyte Sedimentation Rate 7.4 Manual Cell Counts, Manual Hemoglobin Methods, and Hematology Quality Control
8 Chapter 8: Hematology: Blood Cell Morphology, Bone Marrow, and Hematologic Disorders
8.1 Normal Erythropoiesis and Erythrocyte Morphologic Abnormalities 8.2 Anemias: Classification, Iron Deficiency, Megaloblastic, Hemolytic, and Hemoglobinopathies 8.3 Normal Leukopoiesis, Leukocyte Differential, and Non-Malignant White Cell Alterations 8.4 Hematologic Malignancies: Acute and Chronic Leukemias, Myeloproliferative and Lymphoproliferative Disorders 8.5 Peripheral Blood Smear Preparation and Staining, Bone Marrow Examination, and Cytochemistry
9 Chapter 9: Hemostasis: Coagulation and Platelet Function Testing and Hemostatic Disorders
9.1 Mechanisms of Primary and Secondary Hemostasis, Fibrinolysis, and Natural Inhibitors 9.2 Coagulation Laboratory Testing: PT/INR, aPTT, Fibrinogen, Thrombin Time, and Mixing Studies 9.3 Hemostatic and Thrombotic Disorders: Hemophilias, von Willebrand Disease, DIC, and Thrombophilias 9.4 Bleeding Time, Clotting Time, Platelet Function, and Special Hematology Tests
10 Chapter 10: Immunohematology: Blood Group Systems and Antiglobulin Testing
10.1 The ABO Blood Group System, Genetics, Subgroups, and Forward/Reverse Typing Discrepancies 10.2 The Rh Blood Group System, Weak D Testing, and Other Major Blood Group Systems 10.3 Antiglobulin Testing, Elution, Adsorption, and Special Antibody Procedures
11 Chapter 11: Blood Banking: Donor Operations, Component Therapy, and Adverse Reactions
11.1 Donor Selection, Physical Examination, Screening, and Mandatory Infectious Marker Testing 11.2 Blood Component Preparation, Storage, Expiration, and Indications for Transfusion 11.3 Pre-Transfusion Compatibility Testing and Transfusion Reactions 11.4 Hemolytic Disease of the Fetus and Newborn (HDFN) and Rh Immune Globulin
12 Chapter 12: Clinical Serology and Immunology
12.1 Principles of Immunology: Antigens, Antibodies, Complement, and Immune Responses 12.2 Serologic Testing Methodologies: Agglutination, Precipitation, Flocculation, and Labeled Immunoassays 12.3 Infectious Disease Serology: Syphilis, Viral Hepatitis Markers, HIV, Dengue, and Febrile Agglutinins 12.4 Autoimmune Serology, Hypersensitivity, Immunodeficiencies, and Histocompatibility (HLA)
13 Chapter 13: Clinical Microscopy: Urinalysis and Renal Pathology
13.1 Renal Physiology, Urine Formation, and Physical Examination of Urine 13.2 Chemical Examination of Urine: Reagent Strip Principles, Interferences, and Confirmatory Tests 13.3 Microscopic Examination of Urine Sediment: Cells, Casts, Crystals, and Contaminants 13.4 Renal Calculi, Glomerular/Tubular/Interstitial Renal Diseases, and Urinalysis Quality Control
14 Chapter 14: Clinical Microscopy: Body Fluids, Fecal Analysis, and Gastric, Duodenal, and Respiratory Specimens
14.1 Cerebrospinal Fluid Analysis: Collection, Cell Counts, Chemistry, and Microbiology 14.2 Serous Fluids (Pleural, Pericardial, Peritoneal: Transudates vs Exudates) and Synovial Fluid Analysis 14.3 Seminal Fluid and Amniotic Fluid Analysis 14.4 Fecal Analysis: Macroscopic, Microscopic, and Chemical Examination of Stool 14.5 Gastric Fluid, Duodenal Contents, Sputum, and Bronchoalveolar Specimens
15 Chapter 15: Histopathologic Techniques and Cytotechnology
15.1 Tissue Preservation, Fixation, Decalcification, and Processing Steps 15.2 Microtomy, Sectioning Artifacts, Hematoxylin and Eosin Staining, and Special Stains 15.3 Cytotechnology: Specimen Collection, Fixation, Papanicolaou Staining, and the Bethesda System 15.4 Special Procedures: Frozen Sections, Special Embedding, Immunohistochemistry, Electron Microscopy, Autopsy, Museum Techniques, and Laboratory Records
16 Chapter 16: Medical Technology Laws, Related Laws, and Ethics
16.1 Republic Act No. 5527 (The Philippine Medical Technology Act of 1969) and Key Amendments 16.2 Related Philippine Healthcare Laws, Code of Ethics, and Bioethics
11.4 Hemolytic Disease of the Fetus and Newborn (HDFN) and Rh Immune Globulin
Key Takeaways Explain This Topic AI
HDFN occurs when maternal IgG antibodies cross the placenta through the neonatal Fc receptor and destroy fetal red cells carrying the corresponding paternal antigen.
Rh HDFN usually spares the first pregnancy and gives a strongly positive cord DAT, while ABO HDFN often affects the first group A or B infant of a group O mother and gives a weak or negative DAT.
One 300 µg (1,500 IU) RhIg dose covers 30 mL of fetal whole blood, and Kleihauer-Betke doses round down below 0.5 or up at 0.5 and above, then add one vial.
Cord blood testing includes ABO forward typing only, Rh(D) typing with weak D when relevant, and a DAT on thoroughly washed cells.
Red cells for exchange transfusion are group O, antigen-negative, compatible with maternal plasma, irradiated, CMV-safe, hemoglobin S-negative, and fresh.
Last updated: October 2026
Hemolytic Disease of the Fetus and Newborn (HDFN) and Rh Immune Globulin
Hemolytic disease of the fetus and newborn links three blood bank skills that the board tests together: recognizing which maternal antibodies are dangerous, monitoring an alloimmunized pregnancy, and preventing anti-D formation with correctly dosed Rh immune globulin (RhIg). It also covers the neonatal end of the problem: cord blood testing and choosing blood for intrauterine and exchange transfusion. Rh(D)-negative mothers are uncommon among Filipinos, so ABO HDFN is the form most often seen in Philippine nurseries, but anti-D prophylaxis and fetomaternal hemorrhage calculations remain standard board material.
- 1. Pathophysiology and Rh Versus ABO HDFN
- Pathophysiology of Maternal Alloimmunization
HDFN develops when maternal IgG antibodies directed against a paternal erythrocyte antigen inherited by the fetus cross the placenta via the neonatal Fc receptor ( FcRn ). The IgG antibodies bind fetal red blood cells, which are subsequently destroyed via extravascular clearance by fetal splenic macrophages. ┌────────────────────────────────────────────────────────────────────────────────────────┐
- │ Pathophysiological Cascade of In Utero HDFN │
- ├────────────────────────────────────────────────────────────────────────────────────────┤
- │ Maternal IgG Alloantibody (e.g., anti-D) crosses placenta via FcRn │
- │ │ │
- │ ▼ │
- │ Binds fetal antigen-positive red blood cells → Splenic macrophage clearance │
- │ │ │
- │ ▼ │
- │ Severe Fetal Anemia → Extramedullary hematopoiesis (Hepatosplenomegaly) │
- │ │ │
- │ ▼ │
- │ Hepatic portal hypertension + Hypoalbuminemia + High-output cardiac failure │
- │ │ │
- │ ▼ │
- │ HYDROPS FETALIS (Generalized anasarca, pericardial effusion, ascites, fetal demise) │
- ├────────────────────────────────────────────────────────────────────────────────────────┤
- │ Post-Delivery Neonatal Cascade │
- │ │
- │ In utero: Maternal placenta clears unconjugated bilirubin. │
- │ At birth: Massive ongoing hemolysis + Immature neonatal UDP-glucuronosyltransferase. │
- │ Rapid surge in unconjugated bilirubin → Crosses immature blood-brain barrier │
- │ │ │
- │ ▼ │
- │ KERNICTERUS (Bilirubin encephalopathy, basal ganglia necrosis, permanent brain damage) │
- └────────────────────────────────────────────────────────────────────────────────────────┘
- Comparative Analysis: Rh HDFN vs. ABO HDFN
- Diagnostic Parameter Rh HDFN (anti-D) ABO HDFN (anti-A,B)
- Maternal Blood Group Rh (D)-negative ( d / d d/d d / d ) Group O
Fetal Blood Group Rh (D)-positive ( D / d D/d D / d or D / D D/D D / D ) Group A (usually A 1 A_1 A 1 ) or Group B
Maternal Antibody Class Immune IgG ( I g G 1 , I g G 3 IgG_1, IgG_3 I g G 1 , I g G 3 ) synthesized after prior exposure Naturally occurring IgG fraction of anti-A,B
Occurrence in 1st Pregnancy Rare / Unlikely ( < 1 % <1\% < 1% ); primary sensitization occurs during delivery of 1st child Frequently occurs in 1st pregnancy ( 40 % – 50 % 40\%\text{--}50\% 40% – 50% of cases)
Clinical Severity Severe to life-threatening ; severe in utero anemia, hydrops fetalis Mild to moderate ; typically mild postpartum jaundice
Direct Antiglobulin Test (DAT) Strongly Positive ( 3 + to 4 + 3+\text{ to }4+ 3 + to 4 + ) on cord blood cells Negative or Weakly Positive ( 1 + 1+ 1 + or microscopic)
Peripheral Blood Smear Reticulocytosis, marked normoblastosis (nucleated RBCs), macrocytes Reticulocytosis, prominent microspherocytes
Antigen Distribution Restricted exclusively to erythroid cell membranes Widely distributed on endothelial tissues and soluble plasma secretions; neutralizes antibody before reaching RBCs
Treatment Modality Intrauterine transfusion, phototherapy, exchange transfusion Phototherapy; exchange transfusion rarely required
2. Rh Immune Globulin (RhIg) Prophylaxis and Fetomaternal Hemorrhage Calculations
Rh Immune Globulin ( RhIg or RhoGAM) is a sterile solution containing high titers of human anti-D IgG . Administering exogenous anti-D to an unsensitized Rh-negative mother masks foreign fetal Rh-positive red cells and induces rapid immune clearance through antibody-mediated immune suppression, preventing active maternal B-cell alloimmunization.
Regulatory Dosing and Indications
Standard Dose : 300 μ g 300\ \mu\text{g} 300 μ g ( 1 , 500 IU 1,500\text{ IU} 1 , 500 IU ) of anti-D.
Coverage : One standard 300 μ g 300\ \mu\text{g} 300 μ g vial neutralizes up to 30 mL 30\text{ mL} 30 mL of fetal Rh-positive whole blood (equivalent to 15 mL 15\text{ mL} 15 mL of packed red blood cells ).
Microdose : A 50 μ g 50\ \mu\text{g} 50 μ g dose is indicated for pregnancy termination, ectopic pregnancy, or chorionic villus sampling occurring prior to 12 weeks 12\text{ weeks} 12 weeks of gestation (fetal blood volume is < 5 mL <5\text{ mL} < 5 mL ).
Routine Prophylaxis Schedule :
Antenatal : Administered at 28 weeks 28\text{ weeks} 28 weeks gestation to all unsensitized Rh-negative pregnant females.
Postpartum : Administered within 72 hours 72\text{ hours} 72 hours of delivery if the newborn is confirmed Rh (D)-positive (or weak D-positive) and the maternal antibody screen confirms absence of active anti-D alloimmunization.
Fetomaternal Hemorrhage (FMH) Assessment
Normal delivery involves an average fetomaternal bleed of < 5 mL <5\text{ mL} < 5 mL . However, obstetrical trauma, placental abruption, or manual extraction can trigger massive fetomaternal hemorrhages exceeding 30 mL 30\text{ mL} 30 mL , necessitating quantitative evaluation and multiple RhIg vials.
Qualitative Screening: The Rosette Test :
Maternal postpartum blood is incubated with reagent anti-D, washed, and mixed with enzyme-treated Rh-positive indicator red blood cells.
Rosettes (clusters of indicator cells surrounding antibody-coated fetal cells) form. The test reliably detects fetomaternal hemorrhage of ≥ 10 mL \ge 10\text{ mL} ≥ 10 mL .
If negative, 1 standard 300 μ g 300\ \mu\text{g} 300 μ g vial is administered.
If positive, quantitative testing is mandatory to calculate the exact number of vials required.
Quantitative Determination: The Kleihauer-Betke (KB) Acid Elution Test :
Biochemical Principle : A thin maternal blood smear is fixed with ethanol and immersed in an acid elution buffer ( pH 3.2 to 3.3 \text{pH } 3.2\text{ to }3.3 pH 3.2 to 3.3 ). Adult maternal hemoglobin ( HbA ) is soluble in acid and elutes out of the cells, leaving behind pale, translucent erythrocyte membranes (" ghost cells "). Fetal hemoglobin ( HbF ) is resistant to acid elution and remains trapped within the cell. Counterstaining with eosin or erythrosin stains fetal red blood cells dark pink/red . ┌────────────────────────────────────────┐
- │ Kleihauer-Betke Acid Elution Smear │
- │ (Count 2,000 Total Cells) │
- └───────────────────┬────────────────────┘
- │
- ▼
- ┌────────────────────────────────────────┐
- │ Step 1: % Fetal Cells │
- │ % = (Fetal Cells / 2,000) x 100 │
- └───────────────────┬────────────────────┘
- │
- ▼
- ┌────────────────────────────────────────┐
- │ Step 2: Fetal Whole Blood (mL) │
- │ Volume = % Fetal Cells x 50 │
- └───────────────────┬────────────────────┘
- │
- ▼
- ┌────────────────────────────────────────┐
- │ Step 3: Calculate RhIg Vials │
- │ Vials = (Fetal Blood Volume / 30) │
- └───────────────────┬────────────────────┘
- │
- ▼
- ┌────────────────────────────────────────┐
- │ Step 4: Standard Rounding │
- │ • Decimal <0.5: Round DOWN + 1 vial │
- │ • Decimal ≥0.5: Round UP + 1 vial │
- └────────────────────────────────────────┘
- The Kleihauer-Betke Mathematical Formulas and Rounding Rules
% Fetal Cells = ( Number of Fetal Cells Counted 2 , 000 Total Maternal Cells ) × 100 \%\text{ Fetal Cells} = \left( \frac{\text{Number of Fetal Cells Counted}}{2,000\text{ Total Maternal Cells}} \right) \times 100 % Fetal Cells = ( 2 , 000 Total Maternal Cells Number of Fetal Cells Counted ) × 100
Volume of Fetal Whole Blood (mL) = % Fetal Cells × 50 \text{Volume of Fetal Whole Blood (mL)} = \%\text{ Fetal Cells} \times 50 Volume of Fetal Whole Blood (mL) = % Fetal Cells × 50
Calculated Number of 300 μ g RhIg Vials = Volume of Fetal Whole Blood (mL) 30 mL \text{Calculated Number of } 300\ \mu\text{g RhIg Vials} = \frac{\text{Volume of Fetal Whole Blood (mL)}}{30\text{ mL}} Calculated Number of 300 μ g RhIg Vials = 30 mL Volume of Fetal Whole Blood (mL)
Strict Blood Banking Rounding Rules for RhIg Dosing :
To prevent catastrophic maternal alloimmunization from under-dosing, analyze the decimal value resulting from dividing by 30:
If the number to the right of the decimal point is less than 0.5 0.5 0.5 ( < 0.5 <0.5 < 0.5 ) , round down to the nearest whole integer, and add 1 1 1 safety vial .
If the number to the right of the decimal point is greater than or equal to 0.5 0.5 0.5 ( ≥ 0.5 \ge 0.5 ≥ 0.5 ) , round up to the next whole integer, and add 1 1 1 safety vial .
Worked Example A ( < 0.5 <0.5 < 0.5 decimal) :
Fetal cells counted: 16 16 16 out of 2 , 000 2,000 2 , 000 .
% Fetal Cells = ( 16 / 2 , 000 ) × 100 = 0.8 % \%\text{ Fetal Cells} = (16 / 2,000) \times 100 = 0.8\% % Fetal Cells = ( 16/2 , 000 ) × 100 = 0.8% .
Fetal Whole Blood = 0.8 × 50 = 40 mL \text{Fetal Whole Blood} = 0.8 \times 50 = 40\text{ mL} Fetal Whole Blood = 0.8 × 50 = 40 mL .
Vials = 40 / 30 = 1.33 \text{Vials} = 40 / 30 = 1.33 Vials = 40/30 = 1.33 .
Because .33 < 0.5 .33 < 0.5 .33 < 0.5 , round down to 1 1 1 , then add 1 1 1 safety vial: 1 + 1 = 2 vials 1 + 1 = \mathbf{2\text{ vials}} 1 + 1 = 2 vials ( 600 μ g 600\ \mu\text{g} 600 μ g ).
Worked Example B ( ≥ 0.5 \ge 0.5 ≥ 0.5 decimal) :
Fetal cells counted: 35 35 35 out of 2 , 000 2,000 2 , 000 .
% Fetal Cells = ( 35 / 2 , 000 ) × 100 = 1.75 % \%\text{ Fetal Cells} = (35 / 2,000) \times 100 = 1.75\% % Fetal Cells = ( 35/2 , 000 ) × 100 = 1.75% .
Fetal Whole Blood = 1.75 × 50 = 87.5 mL \text{Fetal Whole Blood} = 1.75 \times 50 = 87.5\text{ mL} Fetal Whole Blood = 1.75 × 50 = 87.5 mL .
Vials = 87.5 / 30 = 2.92 \text{Vials} = 87.5 / 30 = 2.92 Vials = 87.5/30 = 2.92 .
Because .92 ≥ 0.5 .92 \ge 0.5 .92 ≥ 0.5 , round up to 3 3 3 , then add 1 1 1 safety vial: 3 + 1 = 4 vials 3 + 1 = \mathbf{4\text{ vials}} 3 + 1 = 4 vials ( 1 , 200 μ g 1,200\ \mu\text{g} 1 , 200 μ g ).
3. Prenatal Monitoring of an Alloimmunized Pregnancy
First prenatal visit: ABO and Rh(D) typing and an antibody screen for every pregnant patient, whatever her D type.
Positive screen: Identify the antibody and decide whether it can cause HDFN. Clinically significant antibodies are IgG and react with antigens already present on fetal red cells. Anti-D, anti-c, and anti-K cause the most severe disease. Anti-Lea, anti-Leb, anti-I, and anti-P1 are usually IgM, and Lewis antigens are poorly developed at birth, so they do not cause HDFN.
Antibody titration: The titer is measured with an antiglobulin tube method, and the current sample is tested in parallel with the previous frozen sample so a true rise is not confused with run-to-run variation. Each laboratory defines its critical titer, commonly 16 to 32 for anti-D. A titer at or above the critical value triggers fetal assessment.
Fetal assessment: Middle cerebral artery peak systolic velocity (MCA-PSV) Doppler has largely replaced serial amniocentesis and the Liley ΔA450 curve for detecting fetal anemia. Fetal RHD genotyping from cell-free fetal DNA in maternal plasma, or paternal antigen typing, tells whether the fetus is at risk at all.
Anti-K warning: Anti-K suppresses fetal erythropoiesis as well as destroying red cells, so the titer and the bilirubin level can underestimate how anemic the fetus is.
- 4. Cord Blood Testing and Blood Selection for the Newborn
- Cord Blood Workup
ABO forward typing only. Newborns have not yet made their own anti-A or anti-B, and any antibodies present are maternal IgG, so reverse typing is not performed.
Rh(D) typing , including a weak D test when it decides RhIg eligibility for a D-negative mother.
Direct antiglobulin test (DAT). A strongly positive DAT supports Rh HDFN. In ABO HDFN the DAT is often weak or negative because fetal red cells carry few A and B sites. An eluate tested against A1 and B cells shows which maternal antibody is coating the cells.
Pitfall: Wharton's jelly from the umbilical cord can cause false agglutination. Wash cord cells thoroughly before testing.
Blood for Intrauterine and Exchange Transfusion
Group O red cells (or cells compatible with both mother and infant) that lack the antigen targeted by the maternal antibody, usually D-negative in Rh HDFN.
Crossmatch-compatible with the mother's plasma , because the antibody causing the disease is maternal.
Irradiated to prevent transfusion-associated graft-versus-host disease, CMV-safe (leukoreduced or CMV-seronegative), and hemoglobin S-negative .
Fresh red cells (commonly less than 5 to 7 days old) to limit the potassium load. For exchange transfusion, red cells are often reconstituted with group AB plasma.
A double-volume exchange transfusion removes most antibody-coated red cells (about 85%) and lowers the bilirubin by roughly half, preventing kernicterus. Phototherapy converts unconjugated bilirubin to water-soluble isomers that are excreted without conjugation.